BioSpace News Archive

MezLight LLC is excited to announce the launch of their revolutionary surgical lighting system to provide surgeons with a bright, sterile, and reusable solution for focused light.

Petros Pharmaceuticals, Inc. (Nasdaq: PTPI) (“Petros,” or “the Company”), a leading provider of therapeutics for men’s health, today announces it has been granted a meeting with the U.S. Food and Drug Administration (FDA) to discuss expansions and modifications to the labeling of its erectile dysfunction (ED) medication, STENDRA® (avanafil).

A sarcoma, a rare form of cancer, differs from the more common carcinomas in one major way – they occur in a different type of tissue known as connective tissue.

BiologyWorks™, a medical test developer with a mission to deliver fast, affordable, and accurate molecular testing, today announced the appointment of Hunt Ramsbottom to CEO.

DYSIS Medical Inc. is excited to announce the launch of DYSIS® View, a compact and portable colposcope, which includes the company’s innovative computer-aided cervical mapping technology that helps healthcare professionals detect cervical lesions more clearly.

Health Catalyst, Inc. (“Health Catalyst”, Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, will release its 2021 second quarter operating results on Thursday, August 5, 2021, after market close.

Caribou Biosciences, Inc., (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today the closing of its previously announced initial public offering of 19,000,000 shares of common stock, at a price to the public of $16.00 per share.

“We delivered strong financial results in the second quarter,” said Kevin Lobo, Chair and Chief Executive Officer. “Business momentum continues to build as the pandemic moderates and the integration of Wright Medical is pacing ahead of plan.

Dover Motion, with over 30 years of precision motion design and manufacturing expertise, announces the launch of their newest product: the SmartStage™ XY.

AzurRx BioPharma, Inc. announced the closing of its previously announced underwritten public offering of 10,454,546 shares of common stock of the Company, including the exercise in full by the underwriter of the option to purchase an additional 1,363,636 shares of common stock, at a price to the public of $0.55 per share.